Skip to main content

Table 5 Response to treatment by level of IOP

From: Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study

Per-protocol population

IOP level (mm Hg, 10 am measurement)*

Treatment group

Percentage of patients

IOP change Baseline–month 3 P value

Treatment group

Percentage of patients

IOP change Months 3–6 P value

n

  

Baseline

Month 3

  

Month 6

  

<14

Bim/tim (group 1)

3

70

<0.00001

Dorz/brim/tim (group 1)

58

0.0061

30

<18

31

100

93

<21

95

100

100

<14

Dorz/brim/tim (group 2)

0

38

<0.0001

Bim/tim (group 2)

33

0.1778

26

<18

30

93

87

<21

85

98

96

  1. *The presence of patients in the <14 and <18 mm Hg categories at baseline is due to the fact that baseline IOP was assessed at 8 AM (ie, before instillation) whereas response to treatment was based on IOP measurements taken at 10 AM (ie, 2 hours post-instillation).
  2. 2-tailed, chi-square distribution.
  3. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; IOP: Intraocular pressure.